Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Hepatocellular 59Cholangiocarcinoma 19Carcinoma, Renal Cell 16Biliary Tract Neoplasms 11Stomach Neoplasms 9Thyroid Neoplasms 8Endometrial Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Neoplasms 7Melanoma 6Uterine Cervical Neoplasms 5Thyroid Carcinoma, Anaplastic 5Neuroendocrine Tumors 5Carcinoma, Non-Small-Cell Lung 5Recurrence 4Ovarian Neoplasms 4Liver Neoplasms 4Thyroid Cancer, Papillary 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Neoplasm Metastasis 3Cirrhosis, Familial, with Pulmonary Hypertension 3Brain Neoplasms 3Advanced Biliary Tract Cancer 3Adenocarcinoma, Follicular 3Vulvar Neoplasms 2Uveal Melanoma 2Triple Negative Breast Neoplasms 2Thymoma 2Solid Tumors 2

Interventions

Pemetrexed 5Bevacizumab 5osimertinib 3aflutinib 3Temozolomide 3trastuzumab deruxtecan 2Topotecan 2Spinal Puncture 2Specimen Handling 2Radiotherapy, Intensity-Modulated 2Methotrexate 2Magnetic Resonance Spectroscopy 2tucatinib 1trioctyl phosphine oxide 1pembrolizumab 1nimotuzumab 1merphos 1lenvatinib 1glutathione pegylated liposomal doxorubicin 1epothilone B 1envafolimab 1camrelizumab 1XL647 1Trastuzumab 1Transplantation, Autologous 1Radiotherapy 1Radiosurgery 1Nivolumab 1Mental Status and Dementia Tests 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Meningeal Carcinomatosis × lenvatinib × Clear all
NCT04729348 2025-07-25

Pembrolizumab And Lenvatinib In Leptomeningeal Metastases

Massachusetts General Hospital

Phase 2 Terminated
10 enrolled
CNS

Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡